Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Uprosertib - Laekna Therapeutics

X
Drug Profile

Uprosertib - Laekna Therapeutics

Alternative Names: GSK-2141795; GSK-2141795C; GSK-795; LAE 003; UPB 795

Latest Information Update: 03 Oct 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer Dana-Farber Cancer Institute; Laekna Therapeutics; National Cancer Institute (USA); National Comprehensive Cancer Network; Novartis Oncology; University of California at San Francisco
  • Class Amides; Antineoplastics; Furans; Pyrazoles; Small molecules
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Hereditary haemorrhagic telangiectasia; Proteus syndrome
  • Discontinued Acute myeloid leukaemia; Cervical cancer; Endometrial cancer; Lymphoma; Malignant melanoma; Multiple myeloma; Ovarian cancer; Solid tumours; Triple negative breast cancer; Uveal melanoma

Most Recent Events

  • 14 Sep 2022 Uprosertib - Laekna Therapeutics is available for licensing as of 14 Sep 2022. https://en.laekna.com/ (Laekna Therapeutics pipeline, September 2022)
  • 14 Sep 2022 Discontinued - Phase-II for Malignant melanoma (Combination therapy) in USA (PO) (Laekna Therapeutics pipeline, September 2022)
  • 14 Sep 2022 Discontinued - Phase-II for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Canada (PO) (Laekna Therapeutics Pipeline, September 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top